Aytu BioPharma Inc. (AYTU) exhibits 69.0% gross margins and -35.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 69.0% gross profitability converts into -11.8% operating margin and -35.0% ROIC, outpacing sector cost of capital.
ROIC: -35.0% // GM: 69.0%YoY revenue trajectory of +1.8% paired with -10.06% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +1.8% // FCF YLD: -10.06%Altman Z-Score of 3.80 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.80 // F-SCORE: 5/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $1.98 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend -20.5% net margins.
NET MARGIN: -20.5% // D/E: 0.70x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for AYTU & activate live FRED threshold breach alerts.